We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




X-Ray Scattering Aids New-Drug Search

By Biotechdaily staff writers
Posted on 21 Dec 2004
Researchers have used wide-angle x-ray scattering (WAXS) to study protein-ligand binding and suggest that this technique may prove to be a reliable and high-speed tool for identification of potential new drugs.

Investigators at the Argonne National Laboratory (IL, USA) adapted WAXS technology, usually used in the materials sciences, to study ligand-induced structural changes in proteins. More...
The method is similar to x-ray crystallography but does not require crystallization of the protein. Instead, the protein and ligand are dissolved in an aqueous medium. This is then placed in the path of the x-ray beam, and the scattering pattern for the protein-ligand complex is compared to the pattern demonstrated by the protein alone.

This method allows researchers to determine whether the interaction between the protein and ligand causes changes in the structure of the protein. A ligand that causes structural changes has greater potential as a drug candidate.

"Wide angle x-ray scattering provides a real tool for identifying lead drugs,” said senior author Dr. Lee Makowski, senior investigator in the biosciences division of the Argonne National Laboratory. "It will identify a molecule that is good enough to be developed as a drug. The data collection only takes a couple of minutes, so theoretically an industrial pipeline could be set up that would only be limited by a few minutes per protein-small molecule interaction. Functional cell-based assays currently take weeks, if not months to complete--causing a bottleneck in data collection and analysis.”




Related Links:
Argonne National Laboratory

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
POC Immunoassay Analyzer
Procise DX
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.